Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals, Inc. - Common Stock (NQ:DCPH)

25.59 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million. 
Via Benzinga
Deciphera Raises $150M Via Equity Offering
Via Benzinga
Short Volatility Alert: Deciphera Pharmaceuticals, Inc.
On Friday, shares of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) experienced volatile short activity. After the activity, the stock price moved down -5.45% to $11.27. The overall sentiment for DCPH... 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Preview: Deciphera Pharmaceuticals's Earnings
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Deciphera Pharmaceuticals Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET
Deciphera Pharmaceuticals (NASDAQ:DCPH) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:... 
Via Benzinga
Deciphera's DCC-3116/KRAS Inhibitor Combo Shows Deeper, Longer Tumor Regressions In Preclinical Studies
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Deciphera Pharmaceuticals Inc. Climbs To Annual-High Share Price
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared... 
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Earnings Scheduled For February 8, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that... 
Via Talk Markets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the... 
Via Benzinga
Deciphera: Why There Won’t Be a Quick Recovery
It will take awhile for DCPH stock to recover after major clinical setback 
Via InvestorPlace
691 Stocks Are Down Over 50% This Year
It may be hard to believe because the stock market has been in such an uptrend this year, but there are some interesting statistics for stock performance year-to-date. 
Via Talk Markets
Why Deciphera Pharmaceuticals Shot 12% Higher Today
The company announced a comprehensive restructuring program. 
Via The Motley Fool
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard
Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials. 
Via InvestorPlace
Deciphera Pharma Stock Rises After Announcing Corporate Restructuring
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors... 
Via Benzinga
Don’t Bet on a Deciphera Stock Comeback
Investors weren't wrong in dumping DCPH stock after terrible top-line results for the biotech company's flagship candidate. Avoid for now. 
Via InvestorPlace
Deciphera's Qinlock Approved In Europe For Gastric Cancer
The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal... 
Via Benzinga
Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals
Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip. 
Via InvestorPlace
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.